Delving into the Latest Updates on GD-11 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication

Acute Ischemic Stroke

Inactive Indication-

Originator Organization

Jiangsu Vanguard Pharmaceutical Co.,Ltd.

Active Organization

Jiangsu Vanguard Pharmaceutical Co.,Ltd.

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC18H35NO2

InChIKeyCUPZOFRJARGVBC-UHFFFAOYSA-N

CAS Registry34256-92-3

Phase III Clinical Trial of GD-11 for Injection in the Treatment of Acute Ischemic Stroke - A Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase III Clinical Study with the primary objective of evaluation of the efficacy and safety of GD-11 for injection in the treatment of acute ischemic stroke patients within 48 hours. The subject has a clinical diagnosis of acute ischemic stroke, within 48 hours from stroke onset to start of study treatment, with a National Institutes of Health Stroke Scale (NIHSS) between 6 and 20, had a total score of upper and lower limbs on motor deficits ≥ 2. The primary outcome is the proportion of subjects with mRS score ≤ 1 at 90 days after treatment.

Start Date29 Feb 2024

Sponsor / Collaborator

Jiangsu Vanguard Pharmaceutical Co.,Ltd.

ChiCTR2400080972 / SuspendedPhase 3IIT

Phase III Clinical Trial of GD-11 for Injection in the Treatment of Acute Ischemic Stroke - A Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase III Clinical Study

Start Date19 Feb 2024

Sponsor / Collaborator-

CTR20222803 / RecruitingPhase 2

注射用 GD-11 治疗急性缺血性卒中 II 期临床试验——随机、平行、对照 II 期临床研究

[Translation] Phase II clinical trial of GD-11 for injection in the treatment of acute ischemic stroke - a randomized, parallel, controlled phase II clinical study

探索注射用GD-11不同剂量治疗发病在48h以内的急性缺血性卒中患者的有效性和安全性

[Translation]

To explore the efficacy and safety of different doses of GD-11 for injection in the treatment of patients with acute ischemic stroke within 48 hours of onset

Start Date17 Nov 2022

Sponsor / Collaborator

Jiangsu Vanguard Pharmaceutical Co.,Ltd.

100 Clinical Results associated with GD-11

Login to view more data

100 Translational Medicine associated with GD-11

Login to view more data

100 Patents (Medical) associated with GD-11

Login to view more data

10

Literatures (Medical) associated with GD-11

01 Aug 2024·Chemistry & Biodiversity

Graphiumisides A–D, Monoterpene Glycosides from an Animal‐Derived Endophytic Fungus Graphium sp. GD‐11

Article

Author: Wang, Xiaowei ; Ji, Mengshan ; Guo, Tao ; Wei, Wenjun ; Li, Dongyang ; Zhang, Mingyue ; Zhang, Yuhang ; Wang, Haibo ; Hui, Chengcheng

AbstractFour new monoterpene rhamnosides, graphiumisides A–D (1–4), along with four known steroid compounds (5–8) were isolated from the fermentation extract of animal‐derived endophytic fungus, Graphium sp. GD‐11. The chemical structures of all compounds were elucidated using 1D and 2D NMR, HRESIMS spectroscopic analyses, and other spectroscopic methods. Compounds 1–4 exhibit a distinctive structure connected by one p‐menthane type monoterpene and one L‐rhamnose. This is the first report of monoterpene glycosides from Graphium sp. All compounds (1–8) were tested for cytotoxic activities against four cancer cell lines (HepG2, SMMC7721, SW480, and A549), and only compound 1 showed weak anti‐tumor activity against SMMC7721 cells.

01 Nov 2014·Archives of VirologyQ4 · MEDICINE

Efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the classical swine H1N1 subtype influenza virus in mice and pigs

Q4 · MEDICINE

Article

Author: Meng Huang ; Hai Yu ; Sheng Yang ; Ze-Jun Li ; Fu-ru Yang ; Feng Wen ; Yan-Jun Zhou ; Guang-Zhi Tong

Swine influenza (SI) is an acute, highly contagious respiratory disease caused by swine influenza A viruses (SwIVs), and it poses a potential global threat to human health. Classical H1N1 (cH1N1) SwIVs are still circulating and remain the predominant subtype in the swine population in China. In this study, a high-growth reassortant virus (GD/PR8) harboring the hemagglutinin (HA) and neuraminidase (NA) genes from a novel cH1N1 isolate in China, A/Swine/Guangdong/1/2011 (GD/11) and six internal genes from the high-growth A/Puerto Rico/8/34(PR8) virus was generated by plasmid-based reverse genetics and tested as a candidate seed virus for the preparation of an inactivated vaccine. The protective efficacy of this vaccine was evaluated in mice and pigs challenged with GD/11 virus. Prime and boost inoculation of GD/PR8 vaccine yielded high-titer serum hemagglutination inhibiting (HI) antibodies and IgG antibodies for GD/11 in both mice and pigs. Complete protection of mice and pigs against cH1N1 SIV challenge was observed, with significantly fewer lung lesions and reduced viral shedding in vaccine-inoculated animals compared with unvaccinated control animals. Our data demonstrated that the GD/PR8 may serve as the seed virus for a promising SwIVs vaccine to protect the swine population.

14 Sep 2014·BiofoulingQ3 · BIOLOGY

Antimicrobial and anti-biofilm effect of a novel BODIPY photosensitizer againstPseudomonas aeruginosaPAO1

Q3 · BIOLOGY

Article

Author: Morten Rybtke ; Stefano Banfi ; Tim Tolker-Nielsen ; Paola Barbieri ; Enrico Caruso ; Viviana Teresa Orlandi

Photodynamic therapy (PDT) combines the use of organic dyes (photosensitizers, PSs) and visible light in order to elicit a photo-oxidative stress which causes bacterial death. GD11, a recently synthesized PS belonging to the boron-dipyrromethene (BODIPY) class, was demonstrated to be efficient against planktonic cultures of Pseudomonas aeruginosa, causing a 7 log unit reduction of viable cells when administered at 2.5 μM. The effectiveness of GD11 against P. aeruginosa biofilms grown in flow-cells and microtiter trays was also demonstrated. Confocal laser scanning microscopy of flow-cell-grown biofilms suggests that the treatment has a biocidal effect against bacterial biofilm cells.

100 Deals associated with GD-11

Login to view more data